Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Culmerciclib + Anti-HER2 + Endocrine Therapy as Maintenance in HR+/HER2+ Advanced Breast Cancer
NCT07732491Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of culmerciclib in breast cancer, sponsored by Sun Yat-sen University. Started Aug 2026; status: recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07732491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07732491.